Beohar Nirat, Erdogan Ata K, Lee Daniel C, Sabbah Hani N, Kern Morton J, Teerlink John, Bonow Robert O, Gheorghiade Mihai
Bluhm Cardiovascular Institute, Feinberg School of Medicine, Northwestern Memorial Hospital, Chicago, Illinois 60611, USA.
J Am Coll Cardiol. 2008 Jul 1;52(1):13-6. doi: 10.1016/j.jacc.2008.03.037.
Acute heart failure syndromes (AHFS), with a high post-discharge mortality and rehospitalization rate, represent a significant public health burden. The treatment of patients hospitalized with AHFS often includes the use of vasoactive medications such as inotropes and vasodilators. Although such agents are frequently used, their safety and efficacy remain controversial. A significant number of patients with heart failure have underlying coronary artery disease and may be at greater risk from hemodynamic alterations that can diminish coronary perfusion. In AHFS, the relationship among vasoactive medications, coronary perfusion, and potential myocardial injury needs further investigation. Newer techniques now available to evaluate coronary perfusion should provide guidance for the evaluation of existing and future vasoactive therapies for AHFS.
急性心力衰竭综合征(AHFS)出院后死亡率和再住院率较高,是一项重大的公共卫生负担。因AHFS住院的患者治疗通常包括使用血管活性药物,如正性肌力药和血管扩张剂。尽管这类药物经常使用,但其安全性和疗效仍存在争议。大量心力衰竭患者患有潜在的冠状动脉疾病,可能因血流动力学改变导致冠状动脉灌注减少而面临更大风险。在AHFS中,血管活性药物、冠状动脉灌注和潜在心肌损伤之间的关系需要进一步研究。目前可用于评估冠状动脉灌注的新技术应为评估现有的和未来的AHFS血管活性治疗提供指导。